<DOC>
	<DOCNO>NCT01499407</DOCNO>
	<brief_summary>Subjects ST-elevation myocardial infarction randomize , one following : abciximab infusion ClearWay coronary catheter ( C ) , standard abciximab infusion ( A ) , thrombectomy follow abciximab infusion ClearWay catheter ( T+C ) , thrombectomy follow standard abciximab infusion ( T+A ) . The primary objective demonstrate abciximab infusion ClearWay catheter without manual thrombus aspiration ( group C T+C ) result significant reduction intra-stent thrombus formation compare intravenous intracoronary abciximab without thrombectomy ( group A T+A ) . The primary endpoint number cross section thrombus area &gt; 10 % immediately stent implantation assess OCT. Additional angiographic , ECG , clinical endpoint collect adjudicated . This trial currently register ClinicalTrials.gov .</brief_summary>
	<brief_title>Randomized Trial Standard v ClearWay-infused Abciximab Thrombectomy Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>ischemic symptom must present rest last least 10 minute , within 6 hour onset chest pain , ECG change persistent STsegment elevation newonset leave bundle branch block , cardiac marker either normal range elevate ( troponin I T and/or creatine kinasemyocardial band upper limit normal local laboratory assay ) , coronary angiogram must obtain within 6 hour onset symptom , culprit artery must identify native vessel must show significant lesion indicative local thrombosis TIMI flow 02 patient must sign informed consent form prior performance trialrelated procedure . baseline TIMI flow 3 , tortuosity coronary vessel may prevent negotiation target lesion device require protocol , myocardial ischemia precipitate condition atherosclerotic coronary artery disease ( e.g . arrhythmia , severe anemia , hypoxia , thyrotoxicosis , cocaine , severe valvular disease hypotension ) , use fibrinolytic agent within 14 day prior randomization , use abciximab glycoprotein IIb/IIIa inhibitor within 30 day prior randomization , suspect active internal bleeding history hemorrhahagic diathesis , major surgery , biopsy parenchymal organ , eye surgery , serious trauma within 6 week prior randomization , gastrointestinal genitourinary bleed clinical significance within 6 week prior randomization , history cerebrovascular accident ( CVA ) transient ischemic attack within previous 2 year CVA residual neurological deficit , administration oral anticoagulant within 7 day prior randomization unless prothrombin time ≤1.2 time control ( international normalize ratio ≤1.4 ) , ongoing treatment oral anticoagulant , know current platelet count le 100.000 cells/µL , prior know intracranial neoplasm , arteriovenous malformation , aneurysm , aneurysm repair , know allergy abciximab murine protein , know impaired renal function ( estimate glomerular filtration rate &lt; 60 mL/min ) , coexistent condition associate limited life expectancy ( e.g . advanced cancer ) , participation phase another clinical research trial involve evaluation another investigational drug device within 30 day prior randomization , know positive pregnancy test woman childbearing age .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>